▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1543 by analyst upside · 2026-11-12
PTCT
PTC Therapeutics, Inc.
Healthcare · Market Cap $5B · P/E 0x
ANALYST PRICE TARGET
+54.8%
implied upside to consensus target
Current Price $64.91
Consensus Target $100.47
Bull Target $137.0
Bear Target $62.0
Analysts Covering 15
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
9
Hold
2
Sell
0
52-Week Low $58.8
52-Week High $90.87
YTD Return -15.4%
FUNDAMENTALS
Market Cap $5B
P/E Ratio (TTM) N/A
Forward P/E 20.3x
EPS (TTM) $-1.47
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1.2B
Profit Margin -9.2%
52-WEEK RANGE
52-Week Low $58.8
52-Week High $90.87
Current Price $64.91
Bear Target $62.0
Bull Target $137.0
● Now $64.91 ● Target $100.47
TRADING DATA
Avg Volume 1.1M
YTD Return -15.4%
Analyst Count 15
Consensus Buy
Upside to Target +54.8%
Last Updated 2026-11-12

ANALYST SUMMARY

PTC Therapeutics, Inc. (PTCT) is currently trading at $64.91 with a Wall Street consensus price target of $100.47, implying potential upside of 54.8% over the next 12 months. 15 analysts currently cover PTCT, with a consensus rating of Buy - 87% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $137.0, while the most cautious has a target of $62.0.

PTCT operates in the Healthcare sector with a market capitalisation of $5B. The stock is down 15.4% year-to-date and is currently trading near the lower end of its 52-week range of $58.8 – $90.87.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

EWTX +16.5%
Edgewise Therapeutics, Inc.
$5B · P/E 5.6x · Buy
GRFS +17.3%
Grifols, S.A.
$6B · P/E 10.7x · Buy
INDV +36.4%
Indivior Pharmaceuticals Inc
$4B · P/E 10.2x · Buy
CAI +39.8%
Caris Life Sciences, Inc.
$7B · P/E 14.8x · Buy
NVST +14.2%
Envista Holdings Corporation
$4B · P/E 6.6x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PTCT, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup - Reiterated
Buy → Buy 2026-11-02 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-10-30 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-10-30 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-10-30 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-10-08 Building track record
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-09-22 40% win rate (10 calls)
Barclays - Reiterated
Overweight → Overweight 2026-08-14 Building track record
Wells Fargo - Reiterated
Overweight → Overweight 2026-08-13 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
50
out of 100
Coverage depth
21/30
Consensus clarity
7/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →